
Ashby EL, Love S, Kehoe PG. Assessment of activation of the plasma kallikrein-kinin
systemin frontal and temporal cortex in Alzheimer’s disease and vascular dementia.
Neurobiol Aging 2012;33:1345–1355.

Barker R, Ashby EL, Wellington D, Barrow VM, Palmer JC, Kehoe PG, Esiri MM, Love S.
Pathophysiology of white matter perfusion in Alzheimer's disease and vascular
dementia. Brain, 10.1093/brain/awu040.Barker R, Kehoe, PG, Love S. Activators and
inhibitors of the plasminogen system in Alzheimer’s disease. J CellMol Med
2012;16:865-876.

Barker R, Wellington D, Esiri M, Love S. Assessing white matter ischemic damage in
dementia patients by measurement of myelin proteins. J Cereb Blood Flow Metab
2013;33:1050-1057.

Conway ME, El Hindy M, Hezwani M, Hull J, Corry D, Mansbridge A, Hassler M, Patel VB,
Kehoe PG, Love S, Harris M, Forshaw T, Lee CS, El Amraoui F, Wilson A. The branchedchain aminotransferase proteins: novel redox chaperones for protein disulfide
isomerase – implications in Alzheimer’s disease. Antiox Redox Sign,
doi:10.1089/ars.2012.4869.

Durrenberger PF, Fernando FS, Magliozzi R, Kashefi SN, Bonnert TP, Ferrer I, Seilhean
D, Nait-Oumesmar B, Schmitt A, Gebicke-Haerter PJ, Falkai P, Grünblatt E, Palkovits M,
Parchi P, Capellari S, Arzberger T, Kretzschmar H, Roncaroli F, Dexter DT, Reynolds R.
Selection of novel reference genes for use in the human central nervous system: a
BrainNet Europe Study. Acta Neuropathol 2012;124:893-903.

Durrenberger PF, Fernando S, Kashefi SN, Ferrer I, Hauw JJ, Seilhean D, Smith C,
Walker R, Al-Sarraj S, Troakes C, Palkovits M, Kasztner M, Huitinga I, Arzberger T,
Dexter DT, Kretzschmar H, Reynolds R. Effects of antemortem and postmortem
variables on human brain mRNA quality: a BrainNet Europe study. J Neuropathol Exp
Neurol 2010; 69:70-81.

Ferrer I, Armstrong J, Capellari S, Parchi P, Arzberger T, Bell J, Budka H, Ströbel T,
Giaccone G, Rossi G, Bogdanovic N, Fakai P, Schmitt A, Riederers P, Al-Sarraj S, Ravid
R, Kretzschmar H. Effects of formalin fixation, paraffin embedding, and time of storage
on DNA preservation in brain tissue: a BrainNet Europe study. Brain Pathol
2007;17:297-303.

Ferrer I, Martinez A, Boluda S, Parchi P, Barrachina M. Brain banks: benefits, limitations
and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell
Tissue Bank 2008;9:181-94.

Ferrer I, Santpere G, Arzberger T, Bell J, Blanco R, Boluda S, Budka H, Carmona M,
Giaccone G, Krebs B, Limido L, Parchi P, Puig B, Strammiello R, Ströbel T, Kretzschmar
H. Brain protein preservation largely depends on the post-mortem temperature of
storage. Implications for the study of proteins in human neurological diseases and for
the management of brain banks. A BrainNet Europe Study. J Neuropathol Exp Neurol
2007;66:35-46.

Fraser T, Tayler H, Love S. Low-temperature improved-throughput method for analysis
of brain fatty acids and assessment of their post-mortem stability.J Neurosci Method,
2008;169: 135–140.

Glennon EBC, Whitehouse IJ, Miners JS, Kehoe PG, Love S, Kellett KAB, Hooper NM.
BIN1 is decreased in sporadic but not familial Alzheimer’s disease or in aging. PLoS One
2013; 8: e78806. doi: 10.1371/journal.pone.0078806.

Grünblatt E, Monoranuy CM, Apfelbacher M, Keller D, Michel TM, Alafuzoff I, Ferrer I,
Al-Saraj S, Keyvanbi K, Schmitt A, Falkai P, Schiienhelm J, McLean C, Halliday GM,
Harper C, Deckert J, Roggendorf W, Riederer P. Tryptophan is a marker of human
postmortem brain tissue quality. J Neurochem 2009;110:1400-1408.

Love S, Chalmers K, Ince P, Esiri M, Attems J, Jellinger K, Yamada M, McCarron M,
Minett T, Matthews F, Greenberg S, Mann D, Kehoe PG. Development, appraisal,
validation and implementation of a consensus protocol for the assessment of cerebral
amyloid angiopathy in post-mortem brain tissue. Am J Neurodegen Dis, in press.

Monoranu C, Apfelbacher M, Grünblatt E, Puppe B, Alafuzoff I, Ferrer I, Al-Saraj S,
Keyvani K, Schmitt A, Falkai P, Schittenheim J, Halliday G, Kril J, Harper C, Riederer P,
Roggendorf W. pH measurement as quality control on human postmortem brain tissue.
A study of the BrainNet Europe Consortium. Neuropathol Appl Neurobiol 2009;35:329337.

Sherwood KR, Head MW, Walker R, Smith C, Ironside JW, Fazakerley JK. RNA integrity
in post-mortem human vCJD and control brain tissue. Neuropathol Appl Neurobiol
2011;37:633-42.

Sherwood KR, Head MW, Walker R, Smith C, Ironside JW, Fazakerley JK. A new index
of agonal state for neurological disease. Neuropathol Appl Neurobiol 2011;37:672-5.

Stan AD, Ghose S, Gao XM, Roberts RC, Lewis-Amezcua K, Hatanpaa KJ, et al. Human
postmortem tissue: What quality markers matter? Brain Res 2006;1123:1-11.

Tomita H, Vawter MP, Walsh DM, Evans SJ, Choudary PV, Li J. Effect of agonal and
postmortem factors on gene expression profile: quality control in microarray analyses
of postmortem human brain. Biol Psychiatry 2004;55:346-52.

Whitehouse IJ, Miners JS, Glennon EBC, Kehoe PG, Love S, Kellett KAB, Hooper NM.
Prion protein but not contactin 5 is decreased in Alzheimer’s brain and inversely
correlates with BACE1 activity amyloid-β levels and Braak stage. PLoS One
2013;8:e59554. doi: 10.1371/journal.pone.0059554.

Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, Neal JW, Love S,
Nicoll JAR, Boche D. Inflammatory components in human Alzheimer’s disease and
following active Aβ42 immunisation. Brain 2013; 136: 2677-2696.